USA FINANCIAL FORMULAS

Position in MRK — Merck & Co., Inc.

CIK 1633716 ADA, MI

Position in MRK

as of Mar 31, 2026 · filed Apr 14, 2026 Compact

Position Value

$891,348

+$722,258 QoQ

Shares Held

7,410

+397.6% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.82%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

19 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Mar 31, 2026

USA FINANCIAL FORMULAS holds $3,801,551 across 6 Drug Manufacturers - General names. MRK ranks #2 (23.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GILD	Gilead Sciences, Inc.	9,804	$1,366,383
2	MRK	Merck & Co., Inc. This page	7,410	$891,348
3	JNJ	Johnson & Johnson	2,894	$707,409
4	AMGN	Amgen Inc	1,862	$655,144
5	BMY	Bristol Myers Squibb Co	2,978	$180,615
6	ABBV	AbbVie Inc.	3	$652

19 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$891,348	7,410	+397.6%	Shares	Sole	2026-04-14
2024-09-30	$169,090	1,489	-67.1%	Shares	Sole	2024-10-08
2024-06-30	$560,690	4,529	+39.0%	Shares	Sole	2024-07-12
2024-03-31	$430,025	3,259	+757.6%	Shares	Sole	2024-04-30
2023-12-31	$41,427	380	-95.9%	Shares	Sole	2024-02-07
2023-09-30	$964,744	9,371	-1.0%	Shares	Sole	2023-11-27
2023-06-30	$1,091,820	9,462	-15.7%	Shares	Sole	2023-11-27
2023-03-31	$1,193,589	11,219	-26.7%	Shares	Sole	2023-11-27
2022-09-30	$1,318,152	15,306	+60.6%	Shares	Sole	2022-10-24
2022-06-30	$869,123	9,533	+761.9%	Shares	Sole	2022-08-15
2022-03-31	$90,747	1,106	-10.2%	Shares	Sole	2022-08-16
2021-12-31	$94,343	1,231	+4634.6%	Shares	Sole	2022-02-10
2021-09-30	$1,952	26	0.0%	Shares	Sole	2021-11-08
2021-06-30	$2,022	26	-76.4%	Shares	Sole	2021-07-29
2021-03-31	$8,479	110	+8.9%	Shares	Sole	2021-05-06
2020-12-31	$8,261	101	+741.7%	Shares	Sole	2021-01-29
2020-09-30	$995	12	-76.0%	Shares	Sole	2020-10-09
2020-06-30	$3,866	50	+19.0%	Shares	Sole	2020-08-11
2020-03-31	$3,231	42	—	Shares	Sole	2020-04-13
No filing history on record for this holder in this stock.